Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Roche shares fall after Alzheimer's drug trials fail to meet primary goals

Published 11/14/2022, 05:35 AM
Updated 11/14/2022, 05:39 AM
© Reuters.

By Scott Kanowsky -- Roche Holding AG Participation (SIX:ROG) says two long-awaited late-stage studies showed that its Alzheimer's disease treatment failed to stem a slide in the cognitive abilities of people with an early form of the illness.

In a statement on Monday, the Swiss pharmaceutical firm said results from the Phase III trials of the drug - known as gantenerumab - failed to meet their "primary endpoint" of slowing the clinical decline in patients with mild dementia due to Alzheimer's.

Shares in Roche fell in early trading.

"So many of our families have been directly affected by Alzheimer's, so this news is very disappointing to deliver," said Roche chief medical officer Levi Garraway.

The failure of gantenerumab deals a blow to the so-called amyloid hypothesis or a theory that the clearing of toxic cells clumping together in the brain will help ease cognitive loss in people suffering from Alzheimer's. Roche, as well as rival Eli Lilly and Company (NYSE:LLY) and Japan's Eisai (TYO:4523), have been aiming to create a medicine that harnesses this theory, with a successful treatment set to potentially generate billions of dollars in sales.

Alzheimer's disease - a neurological disorder that causes the brain to shrink in size and cells to die - has impacted an estimated 55 million people worldwide as recently as 2020, according to the advocacy group Alzheimer's Disease International. There is currently no known cure.

In a note to clients, analysts at Stifel called Roche's announcement a "major negative" for the firm.

"This is the end of this development, that will have to be removed from the sales models. It also removes a significant growth driver for the company over the next few years," the analysts said.

Roche's 2023 financial guidance will now be "highly exposed" to a potential hit worth CHF 3-4 billion (CHF 1 = $1.0552), resulting in a no-growth year for the group, they added.

Latest comments

JJ JJ u r too funnie
Did they test the medication on John Biden??
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.